Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SPRB Spruce Biosciences, Inc.

Market Closed 05-17 16:00:00 EDT

0.7500

-0.0199

-2.58%

盘后0.7501

+0.0001+0.01%

18:56 EDT

High0.7689	Low0.7388	Vol602.30K
Open0.7527	D1 Closing0.7699	Amplitude3.91%
Mkt Cap30.86M	Tradable Cap11.90M	Total Shares41.15M
T/O454.32K	T/O Rate3.80%	Tradable Shares15.86M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SPRB","market":"US","secType":"STK","nameCN":"Spruce Biosciences, Inc.","latestPrice":0.75,"timestamp":1715976000000,"preClose":0.7699,"halted":0,"volume":602302,"hourTrading":{"tag":"盘后","latestPrice":0.7501,"preClose":0.75,"latestTime":"18:56 EDT","volume":586,"amount":439.6248,"timestamp":1715986597861},"delay":0,"floatShares":15864609,"shares":41152616,"eps":-1.145647,"marketStatus":"Market Closed","change":-0.0199,"latestTime":"05-17 16:00:00 EDT","open":0.7527,"high":0.7689,"low":0.7388,"amount":454324.65013739996,"amplitude":0.039096,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.145647,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1716192000000},"marketStatusCode":7,"adr":0,"listingDate":1602216000000,"exchange":"NASDAQ","adjPreClose":0.7699,"preHourTrading":{"tag":"盘前","latestPrice":0.7694,"preClose":0.7699,"latestTime":"09:28 EDT","volume":2139,"amount":1638.931746,"timestamp":1715952522869},"postHourTrading":{"tag":"盘后","latestPrice":0.7501,"preClose":0.75,"latestTime":"18:56 EDT","volume":586,"amount":439.6248,"timestamp":1715986597861},"volumeRatio":1.194956127632651},"requestUrl":"/m/hq/s/SPRB","defaultTab":"news","newsList":[{"id":"2435762692","title":"Hold Rating on Spruce Biosciences Amid Clinical Trial Uncertainties and Rising Competition","url":"https://stock-news.laohu8.com/highlight/detail?id=2435762692","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435762692?lang=en_us&edition=fundamental","pubTime":"2024-05-16 16:09","pubTimestamp":1715846964,"startTime":"0","endTime":"0","summary":"Spruce Biosciences (SPRB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on May 14. Analyst Joseph Schwar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/hold-rating-on-spruce-biosciences-amid-clinical-trial-uncertainties-and-rising-competition?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/hold-rating-on-spruce-biosciences-amid-clinical-trial-uncertainties-and-rising-competition?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435950439","title":"Spruce Biosciences Faces Nasdaq Delisting Threat Over Low Stock Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2435950439","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435950439?lang=en_us&edition=fundamental","pubTime":"2024-05-15 14:00","pubTimestamp":1715752821,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc. (SPRB) has disclosed a new risk, in the Share Price & Shareholder Rights category. Spruce Biosciences, Inc. is confronted ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-faces-nasdaq-delisting-threat-over-low-stock-prices?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-faces-nasdaq-delisting-threat-over-low-stock-prices?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435522678","title":"Buy Rating Affirmed for Spruce Biosciences Amid Upcoming Trial Data and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2435522678","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435522678?lang=en_us&edition=fundamental","pubTime":"2024-05-15 06:45","pubTimestamp":1715726730,"startTime":"0","endTime":"0","summary":"Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Spruce Biosciences (SPRB – Research Report), retaining the price target of $...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-spruce-biosciences-amid-upcoming-trial-data-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-spruce-biosciences-amid-upcoming-trial-data-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435457596","title":"H.C. Wainwright Sticks to Their Hold Rating for Spruce Biosciences (SPRB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435457596","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435457596?lang=en_us&edition=fundamental","pubTime":"2024-05-14 18:37","pubTimestamp":1715683045,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju maintained a Hold rating on Spruce Biosciences (SPRB – Research Report) today. The company’s shares closed ye...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-hold-rating-for-spruce-biosciences-sprb?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-sticks-to-their-hold-rating-for-spruce-biosciences-sprb?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435858825","title":"Spruce Biosciences GAAP EPS of -$0.28 beats by $0.02, revenue of $2M beats by $0.84M","url":"https://stock-news.laohu8.com/highlight/detail?id=2435858825","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435858825?lang=en_us&edition=fundamental","pubTime":"2024-05-14 05:38","pubTimestamp":1715636281,"startTime":"0","endTime":"0","summary":"Spruce Biosciences press release  (NASDAQ:SPRB): Q1  GAAP EPS of -$0.28  beats by $0.02.\nRevenue of $2M (+2.0% Y/Y)  beats by $0.84M.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4105539-spruce-biosciences-gaap-eps-of-0_28-beats-0_02-revenue-of-2m-beats-0_84m","is_publish_highlight":false,"gpt_icon":0},{"id":"2435589517","title":"Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2435589517","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2435589517?lang=en_us&edition=fundamental","pubTime":"2024-05-14 05:10","pubTimestamp":1715634605,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc.  came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this company would post a loss of $0.41 per share when it actually produced a loss of $0.23, delivering a surprise of 43.90%.Spruce Biosciences , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $2 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 79.55%. This compares to year-ago revenues of $1.96 million. The company has topped consensus revenue estimates three times over the last four quarters.Spruce Biosciences shares have lost about 71.6% since the beginning of the year versus the S&P 500's gain of 9.5%.While Spruce Biosciences has underperformed the market so far this year, ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d6hN0_BhikrNdWTnix6fng--~B/aD03NDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d6hN0_BhikrNdWTnix6fng--~B/aD03NDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-inc-sprb-reports-211005311.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435009793","title":"Spruce Biosciences Inc reports results for the quarter ended in January - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2435009793","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2435009793?lang=en_us&edition=fundamental","pubTime":"2024-05-14 04:46","pubTimestamp":1715633166,"startTime":"0","endTime":"0","summary":"* Spruce Biosciences Inc    reported a quarterly adjusted loss of 28 cents per share for the quarter ended in January, higher than the same quarter last year, when the company reported EPS of -40 cent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2435302360","title":"Spruce Biosciences Q1 EPS $(0.28) Beats $(0.29) Estimate, Sales $2.02M Beat $1.16M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2435302360","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2435302360?lang=en_us&edition=fundamental","pubTime":"2024-05-14 04:05","pubTimestamp":1715630746,"startTime":"0","endTime":"0","summary":"Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 3.45 percent. This is a 30 percent increase over losses of $(0.40) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38800159/spruce-biosciences-q1-eps-0-28-beats-0-29-estimate-sales-2-02m-beat-1-16m-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2435307803","title":"Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2435307803","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2435307803?lang=en_us&edition=fundamental","pubTime":"2024-05-14 04:01","pubTimestamp":1715630460,"startTime":"0","endTime":"0","summary":"Analyses of Data from CAHmelia-203 in Adult Congenital Adrenal Hyperplasia  Demonstrate Correlation Between Tildacerfont Response and Baseline Glucocorticoid  Dose and Drug Compliance. Posters Highlighting Baseline Characteristics from the CAHmelia Program in Adult CAH and CAHptain-205 Study in Pediatric CAH Presented at the Pediatric Endocrine Society  2024 Annual Meeting. Higher GC doses at baseline were associated with larger placebo-adjusted reductions from baseline in A4 after the initial 12 weeks of treatment with tildacerfont. Patients with a baseline GC dose of 15mg hydrocortisone equivalents  had a mean placebo-adjusted increase from baseline in A4 of 18% after 12 weeks of treatment with tildacerfont. By contrast, patients with a baseline GC dose of 55mg HCe had a mean placebo-adjusted decrease from baseline in A4 of 27% after 12 weeks of treatment with tildacerfont. Patients in CAHmelia-203 enrolled with a mean baseline A4 level of more than five times above the upper limit o","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WeNSlxRNeZisgKp1ktP27A--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2fe7902bf2ad4e2dc9755b95a6918d14","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WeNSlxRNeZisgKp1ktP27A--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2fe7902bf2ad4e2dc9755b95a6918d14"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-reports-first-quarter-200100041.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434657208","title":"Spruce Biosciences Inc    expected to post a loss of 29 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2434657208","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434657208?lang=en_us&edition=fundamental","pubTime":"2024-05-10 23:58","pubTimestamp":1715356716,"startTime":"0","endTime":"0","summary":"* Spruce Biosciences Inc     is expected to show a fall in quarterly revenue when it reports  results on May 13 (estimated) for the period ending March 31 2024   * The South San Francisco California-b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432637053","title":"Spruce Biosciences to Participate in May Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2432637053","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2432637053?lang=en_us&edition=fundamental","pubTime":"2024-05-02 04:05","pubTimestamp":1714593900,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., May 01, 2024----Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in two upcoming investor conferences taking place in May.The JMP Securities Life Sciences ConferenceDate: May 13-14, 2024Format: Fireside chat  and 1x1 meetings. The live webcast for each conference presentation can be accessed on the events section of the company’s investor relations website and will be available for replay after the conclusion of the live presentations for approximately 90 days.Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/RwgsUtu_JFNOPvL8F5gJcA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/1471a1956562e68a409bf81497488e80","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/RwgsUtu_JFNOPvL8F5gJcA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/1471a1956562e68a409bf81497488e80"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-participate-may-investor-200500869.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432158718","title":"Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2432158718","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2432158718?lang=en_us&edition=fundamental","pubTime":"2024-05-01 04:05","pubTimestamp":1714507500,"startTime":"0","endTime":"0","summary":"Presentation to highlight baseline characteristics of Spruce’s CAHptain program evaluating tildacerfont in pediatric congenital adrenal hyperplasia . The company is also highlighting baseline characteristics from its CAHmelia program evaluating tildacerfont in adult CAH in a poster presentation. SOUTH SAN FRANCISCO, Calif., April 30, 2024----Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that an accepted abstract highlighting baseline characteristics from the company’s CAHptain Phase 2 study evaluating tildacerfont in children and adolescents with congenital adrenal hyperplasia  will be presented at the Pediatric Endocrine Society  2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.In addition, a submitted abstract highlighting baseline characteristics from Spruce’s CAHmelia program evaluating tildacerfont in adult CA","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/DCr281Hby4WfAoXQf7Bi4w--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cdc988e78eea366a1cfeb554cbf8090a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/DCr281Hby4WfAoXQf7Bi4w--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/cdc988e78eea366a1cfeb554cbf8090a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-announces-additional-poster-200500209.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429909331","title":"Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2429909331","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2429909331?lang=en_us&edition=fundamental","pubTime":"2024-04-23 04:05","pubTimestamp":1713816300,"startTime":"0","endTime":"0","summary":"Presentation to highlight baseline characteristics of Spruce’s CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia , as an illustration of outcomes of current pediatric CAH disease management. SOUTH SAN FRANCISCO, Calif., April 22, 2024----Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the Pediatric Endocrine Society  2024 Annual Meeting taking place May 2-5, 2024, in Chicago, IL.The poster will be available on the company’s website beginning May 3, 2024 at 12:15 p.m. CT. Access more information about PES 2024 here.Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholl","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0b_G.ebtEYuorHOthsvA0A--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ab6be0539f70214c04978915874affc1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0b_G.ebtEYuorHOthsvA0A--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/ab6be0539f70214c04978915874affc1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-announces-upcoming-poster-200500070.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422945932","title":"Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2422945932","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2422945932?lang=en_us&edition=fundamental","pubTime":"2024-03-28 00:00","pubTimestamp":1711555209,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc.  appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 . This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a changing earnings picture is a powerful factor influencing near-term stock price movements, the Zacks rating system is very useful for individual investors. They may find it difficult to make decisions based on rating upgrades by Wall Street analysts, as these are mostly driven by subjective factors that are hard to see and measure in real time.As such, the Zacks rating upgrade for Spruce Biosciences is essentially a positive comment on its earnings outlook that could have a favorable impact on its ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7h8ntzJXcDOdVmDKQ08gRg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7h8ntzJXcDOdVmDKQ08gRg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-sprb-upgraded-buy-160009722.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421353045","title":"Revenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2421353045","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2421353045?lang=en_us&edition=fundamental","pubTime":"2024-03-23 20:47","pubTimestamp":1711198038,"startTime":"0","endTime":"0","summary":"The latest analyst coverage could presage a bad day for Spruce Biosciences, Inc. , with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Revenue estimates were cut sharply as analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well.Following the latest downgrade, the seven analysts covering Spruce Biosciences provided consensus estimates of US$4.6m revenue in 2024, which would reflect a stressful 54% decline on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$5.3m in 2024. The consensus view seems to have become more pessimistic on Spruce Biosciences, noting the substantial drop in revenue estimates in this update.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revenue-downgrade-heres-analysts-forecast-124718066.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2421026399","title":"Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2421026399","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2421026399?lang=en_us&edition=fundamental","pubTime":"2024-03-21 22:20","pubTimestamp":1711030800,"startTime":"0","endTime":"0","summary":"Spruce Biosciences SPRB stock has declined 86.1% in the past month due to the failure of a key study on its lead pipeline candidate, tildacerfont.Spruce Biosciences is developing tildacerfont in the CAHmelia program as a non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia . The CAHmelia program in adult classic CAH comprises two phase IIb studies. The first study is CAHmelia-203, which assesses androstenedione  reduction in adult CAH patients with severe hyperandrogenemia, a difficult-to-treat CAH patient population.Last week, Spruce Biosciences announced that the CAHmelia-203 phase IIb study of tildacerfont in adult patients with CAH failed to meet the primary efficacy endpoint of change in A4 from baseline to week 12. In the study, a 200mg once-daily dose of tildacerfont demonstrated a placebo-adjusted reduction of -2.6% in A4 at week 12, which was not statistically significant. Spruce Biosciences said the negative outcome of the study","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-sprb-falls-86-142000488.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2420976429","title":"Spruce Biosciences’ Compliance Hurdle: Navigating Sarbanes-Oxley to Protect Market Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2420976429","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2420976429?lang=en_us&edition=fundamental","pubTime":"2024-03-20 14:02","pubTimestamp":1710914552,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc. (SPRB) has disclosed a new risk, in the Accounting & Financial Operations category. Spruce Biosciences, Inc. faces signifi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-compliance-hurdle-navigating-sarbanes-oxley-to-protect-market-value?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/spruce-biosciences-compliance-hurdle-navigating-sarbanes-oxley-to-protect-market-value?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2420185034","title":"Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Spruce Biosciences (SPRB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2420185034","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2420185034?lang=en_us&edition=fundamental","pubTime":"2024-03-18 12:30","pubTimestamp":1710736216,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Terns Pharmaceuticals (TERN – Research Report) and S...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-terns-pharmaceuticals-tern-and-spruce-biosciences-sprb?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-terns-pharmaceuticals-tern-and-spruce-biosciences-sprb?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2419115638","title":"Spruce Biosciences, Inc. (NASDAQ:SPRB) Just Reported Earnings, And Analysts Cut Their Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2419115638","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2419115638?lang=en_us&edition=fundamental","pubTime":"2024-03-16 20:59","pubTimestamp":1710593980,"startTime":"0","endTime":"0","summary":"Spruce Biosciences, Inc.  investors will be delighted, with the company turning in some strong numbers with its latest results. The results overall were credible, with revenues of US$10m beating expectations by 18%. Statutory losses were US$1.24 per share, 11% below what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest  post-earnings forecasts for next year.NasdaqGS:SPRB Earnings and Revenue Growth March 16th 2024. The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. On the negative side, they also downgraded their revenue estimates, and forecasts imply they will perform worse than the wider industry. Still, earnings per share are more important to value creation f","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fZxxC7WFAddugsI0.C6IZw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spruce-biosciences-inc-nasdaq-sprb-125940811.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2419167668","title":"Spruce Biosciences (NASDAQ:SPRB) Lowered to Sector Perform at Royal Bank of Canada","url":"https://stock-news.laohu8.com/highlight/detail?id=2419167668","media":"Defense World","top":-1,"share":"https://ttm.financial/m/news/2419167668?lang=en_us&edition=fundamental","pubTime":"2024-03-16 15:47","pubTimestamp":1710575253,"startTime":"0","endTime":"0","summary":"Spruce Biosciences (NASDAQ:SPRB) Lowered to Sector Perform at Royal Bank of Canada","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMifGh0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8xNi9zcHJ1Y2UtYmlvc2NpZW5jZXMtbmFzZGFxc3ByYi1sb3dlcmVkLXRvLXNlY3Rvci1wZXJmb3JtLWF0LXJveWFsLWJhbmstb2YtY2FuYWRhLmh0bWzSAQA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMifGh0dHBzOi8vd3d3LmRlZmVuc2V3b3JsZC5uZXQvMjAyNC8wMy8xNi9zcHJ1Y2UtYmlvc2NpZW5jZXMtbmFzZGFxc3ByYi1sb3dlcmVkLXRvLXNlY3Rvci1wZXJmb3JtLWF0LXJveWFsLWJhbmstb2YtY2FuYWRhLmh0bWzSAQA?oc=5","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sprucebiosciences.com","stockEarnings":[{"period":"1week","weight":-0.0993},{"period":"1month","weight":0.062},{"period":"3month","weight":-0.8506},{"period":"6month","weight":-0.4444},{"period":"1year","weight":-0.6681},{"period":"ytd","weight":-0.744}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.33989},{"month":2,"riseRate":0.5,"avgChangeRate":0.009378},{"month":3,"riseRate":0,"avgChangeRate":-0.297383},{"month":4,"riseRate":0,"avgChangeRate":-0.078867},{"month":5,"riseRate":0.5,"avgChangeRate":-0.00062},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.068831},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.022894},{"month":8,"riseRate":0.333333,"avgChangeRate":0.005525},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.195471},{"month":10,"riseRate":0,"avgChangeRate":-0.297781},{"month":11,"riseRate":0.5,"avgChangeRate":0.017474},{"month":12,"riseRate":0.5,"avgChangeRate":0.416923}],"exchange":"NASDAQ","name":"Spruce Biosciences, Inc.","nameEN":"Spruce Biosciences, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Spruce Biosciences, Inc.,SPRB,Spruce Biosciences, Inc.股票,Spruce Biosciences, Inc.股票老虎,Spruce Biosciences, Inc.股票老虎国际,Spruce Biosciences, Inc.行情,Spruce Biosciences, Inc.股票行情,Spruce Biosciences, Inc.股价,Spruce Biosciences, Inc.股市,Spruce Biosciences, Inc.股票价格,Spruce Biosciences, Inc.股票交易,Spruce Biosciences, Inc.股票购买,Spruce Biosciences, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Spruce Biosciences, Inc.(SPRB),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Spruce Biosciences, Inc.(SPRB) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction